BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 28685935)

  • 1. Gastric gland mucin-specific O-glycan expression decreases with tumor progression from precursor lesions to pancreatic cancer.
    Ohya A; Yamanoi K; Shimojo H; Fujii C; Nakayama J
    Cancer Sci; 2017 Sep; 108(9):1897-1902. PubMed ID: 28685935
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Decreased alpha-1,4-linked N-acetylglucosamine glycosylation in biliary tract cancer progression from biliary intraepithelial neoplasia to invasive adenocarcinoma.
    Okumura M; Yamanoi K; Uehara T; Nakayama J
    Cancer Sci; 2020 Dec; 111(12):4629-4635. PubMed ID: 33020993
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reduced αGlcNAc glycosylation on gastric gland mucin is a biomarker of malignant potential for gastric cancer, Barrett's adenocarcinoma, and pancreatic cancer.
    Yamanoi K; Nakayama J
    Histochem Cell Biol; 2018 Jun; 149(6):569-575. PubMed ID: 29658052
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Glycosylation of MUC6 by α1,4-linked N-acetylglucosamine enhances suppression of pancreatic cancer malignancy.
    Yuki A; Fujii C; Yamanoi K; Matoba H; Harumiya S; Kawakubo M; Nakayama J
    Cancer Sci; 2022 Feb; 113(2):576-586. PubMed ID: 34808019
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diffuse MIST1 expression and decreased α1,4-linked N-acetylglucosamine (αGlcNAc) glycosylation on MUC6 are distinct hallmarks for gastric neoplasms showing oxyntic gland differentiation.
    Yamada S; Yamanoi K; Sato Y; Nakayama J
    Histopathology; 2020 Sep; 77(3):413-422. PubMed ID: 32502322
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Decreased expression of gastric gland mucin-specific glycan α1,4-linked N-acetylglucosamine on its scaffold mucin 6 is associated with malignant potential of pyloric gland adenoma of the stomach.
    Yamanoi K; Sekine S; Higuchi K; Kushima R; Nakayama J
    Histopathology; 2015 Dec; 67(6):898-904. PubMed ID: 25929994
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gastric gland mucin-specific O-glycan expression decreases as tumor cells progress from lobular endocervical gland hyperplasia to cervical mucinous carcinoma, gastric type.
    Yamanoi K; Ishii K; Tsukamoto M; Asaka S; Nakayama J
    Virchows Arch; 2018 Sep; 473(3):305-311. PubMed ID: 29845361
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Loss of gastric gland mucin-specific O-glycan is associated with progression of differentiated-type adenocarcinoma of the stomach.
    Shiratsu K; Higuchi K; Nakayama J
    Cancer Sci; 2014 Jan; 105(1):126-33. PubMed ID: 24138592
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reduced gland mucin-specific O-glycan in gastric atrophy: A possible risk factor for differentiated-type adenocarcinoma of the stomach.
    Yamada S; Okamura T; Kobayashi S; Tanaka E; Nakayama J
    J Gastroenterol Hepatol; 2015 Oct; 30(10):1478-84. PubMed ID: 25967588
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Decreased expression of TFF2 and decreased αGlcNAc glycosylation are malignant biomarkers of pyloric gland adenoma of the duodenum.
    Yamanoi K; Fujii C; Nakayama A; Matsuura N; Takatori Y; Kato M; Yahagi N; Nakayama J
    Sci Rep; 2023 Dec; 13(1):21641. PubMed ID: 38062108
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MUC6 expression is a preferable prognostic marker for invasive mucinous adenocarcinoma of the lung.
    Yamanoi K; Fujii C; Yuzuriha H; Kumazawa M; Shimoda M; Emoto K; Asamura H; Nakayama J
    Histochem Cell Biol; 2022 Jun; 157(6):671-684. PubMed ID: 35353213
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Decreased Gastric Gland Mucin-specific
    Ohya A; Matoba H; Fujinaga Y; Nakayama J
    Acta Histochem Cytochem; 2021 Aug; 54(4):115-122. PubMed ID: 34511650
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reduced expression of αGlcNAc in Barrett's oesophagus adjacent to Barrett's adenocarcinoma--a possible biomarker to predict the malignant potential of Barrett's oesophagus.
    Iwaya Y; Hasebe O; Koide N; Kitahara K; Suga T; Shinji A; Muraki T; Yokosawa S; Yamada S; Arakura N; Tanaka E; Nakayama J
    Histopathology; 2014 Mar; 64(4):536-46. PubMed ID: 24117499
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Loss of Trefoil Factor 2 From Pancreatic Duct Glands Promotes Formation of Intraductal Papillary Mucinous Neoplasms in Mice.
    Yamaguchi J; Mino-Kenudson M; Liss AS; Chowdhury S; Wang TC; Fernández-Del Castillo C; Lillemoe KD; Warshaw AL; Thayer SP
    Gastroenterology; 2016 Dec; 151(6):1232-1244.e10. PubMed ID: 27523981
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serine protease inhibitor Kazal type 1 and epidermal growth factor receptor are expressed in pancreatic tubular adenocarcinoma, intraductal papillary mucinous neoplasm, and pancreatic intraepithelial neoplasia.
    Ozaki N; Ohmuraya M; Ida S; Hashimoto D; Ikuta Y; Chikamoto A; Hirota M; Baba H
    J Hepatobiliary Pancreat Sci; 2013 Aug; 20(6):620-7. PubMed ID: 23475261
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preferential expression of MUC6 in oncocytic and pancreatobiliary types of intraductal papillary neoplasms highlights a pyloropancreatic pathway, distinct from the intestinal pathway, in pancreatic carcinogenesis.
    Basturk O; Khayyata S; Klimstra DS; Hruban RH; Zamboni G; Coban I; Adsay NV
    Am J Surg Pathol; 2010 Mar; 34(3):364-70. PubMed ID: 20139757
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intraductal papillary mucinous neoplasm (IPMN) of the pancreas: its histopathologic difference between 2 major types.
    Ban S; Naitoh Y; Mino-Kenudson M; Sakurai T; Kuroda M; Koyama I; Lauwers GY; Shimizu M
    Am J Surg Pathol; 2006 Dec; 30(12):1561-9. PubMed ID: 17122512
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biological similarities and differences between pancreatic intraepithelial neoplasias and intraductal papillary mucinous neoplasms.
    Moriya T; Kimura W; Semba S; Sakurai F; Hirai I; Ma J; Fuse A; Maeda K; Yamakawa M
    Int J Gastrointest Cancer; 2005; 35(2):111-9. PubMed ID: 15879625
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular mechanism of intraductal papillary mucinous neoplasm and intraductal papillary mucinous neoplasm-derived pancreatic ductal adenocarcinoma.
    Fukuda A
    J Hepatobiliary Pancreat Sci; 2015 Jul; 22(7):519-23. PubMed ID: 25900667
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Diagnosis and differential diagnosis of intraductal papillary mucinous neoplasm of pancreas].
    Ji Y; Tan YS; Zhu XZ; Zeng HY; Kuang TT; Jin DY
    Zhonghua Bing Li Xue Za Zhi; 2006 Feb; 35(2):77-81. PubMed ID: 16630480
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.